Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 1, 2026

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Spasmodic DysphoniaLaryngeal DystoniaVoice Tremor

Interventions

DRUG

sodium oxybate

Oral administration of sodium oxybate (1.5g, 2.0g, 2.5g, 3.0g)

Trial Locations (1)

Massachusetts Eye and Ear, Boston

All Listed Sponsors

lead

Kristina Simonyan

OTHER